Uslu, Sadettin2024-11-072024-11-0720202284-2594https://doi.org/10.12890/2020_001731https://hdl.handle.net/11480/11479Cytokine release syndrome (CRS) is a systemic inflammatory response that can be triggered by many factors such as infections. CRS in patients with coronavirus disease 2019 (COVID-19) is life-threatening and can occur very rapidly after COVID-19 diagnosis. Tocilizumab (TCZ), an interleukin-6 (IL-6) inhibitor, may ameliorate the CRS associated with severe COVID-19 and thus improve clinical outcomes. We present a case of life-threatening CRS caused by COVID-19 infection successfully treated with TCZ. © EFIM 2020eninfo:eu-repo/semantics/openAccessCOVID-19Cytokine release syndromeTocilizumabArticle7610.12890/2020_0017312-s2.0-85117084548Q3